Athensmed

Athensmed is an angel investment company specializing in early-stage healthcare and life sciences ventures. Founded by Kustaa Piha, a veteran in medical technology and digital health, the firm has been active since 2016, investing in companies that offer significant health benefits and possess strong business potential. Athensmed typically invests between €125,000 and €500,000 per company, with a sweet spot around €350,000, and can allocate up to €1,000,000 in follow-on investments.

The firm's investment strategy emphasizes sectors such as medical technology, digital health, biotechnology, health diagnostics, and personal health. Athensmed has a history of supporting innovative startups, including Finnadvance, a biotech company developing organ-on-chip technology, and MONCYTE Health, which focuses on personalized treatments for high cholesterol. These investments reflect Athensmed's commitment to advancing healthcare solutions through strategic partnerships with promising early-stage companies.

Athensmed's approach combines financial support with active involvement, often taking board seats to guide the strategic direction of its portfolio companies. This hands-on engagement ensures that investments align with the firm's vision of fostering transformative healthcare innovations. By leveraging its expertise and network, Athensmed aims to accelerate the growth of companies that are poised to make a significant impact in the healthcare sector.